The Calmer Co. Expands Retail Footprint with Coles Approval and U.S. Growth Push
The Calmer Co. International Limited (ASX: CCO) has secured a significant retail milestone after Coles accepted the ranging of its new Fiji Kava® FZZR™ product, while the company simultaneously advances plans to expand into U.S. retail channels. The innovative FZZR™ format allows consumers to drink, chew or consume the product directly, offering a differentiated wellness experience built around proprietary supplement delivery technology. The product will be regulated as a complementary medicine under the TGA framework, enabling the use of standardised kava extracts and flavour innovations such as Piña Colada. The launch is expected to commence in Coles stores during October 2026. The company noted that its Fiji Kava® 150g and 50g products currently rank first and third respectively in Coles’ national Stress category. With distribution now established across both Coles and Woolworths, representing approximately 67% of Australia’s grocery retail footprint, management is leveraging this success to accelerate U.S. expansion, supported by an estimated 10% share of Amazon USA’s kava category and a new partnership with U.S. retail brokerage VDriven.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
The Calmer Co. Expands Retail Footprint with Coles Approval and U.S. Growth Push
The Calmer Co. International Limited (ASX: CCO) has secured a significant retail milestone after Coles accepted the ranging of its new Fiji Kava® FZZR™ product, while the company simultaneously advances plans to expand into U.S. retail channels. The innovative FZZR™ format allows consumers to drink, chew or consume the product directly, offering a differentiated wellness experience built around proprietary supplement delivery technology. The product will be regulated as a complementary medicine under the TGA framework, enabling the use of standardised kava extracts and flavour innovations such as Piña Colada. The launch is expected to commence in Coles stores during October 2026. The company noted that its Fiji Kava® 150g and 50g products currently rank first and third respectively in Coles’ national Stress category. With distribution now established across both Coles and Woolworths, representing approximately 67% of Australia’s grocery retail footprint, management is leveraging this success to accelerate U.S. expansion, supported by an estimated 10% share of Amazon USA’s kava category and a new partnership with U.S. retail brokerage VDriven.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au